Risk factors and the prognosis of sexual dysfunction in male patients with pituitary adenomas: a multivariate analysis

BackgroundSexual dysfunction is a common symptom in patients with schizophrenia, especially in chronically medicated patients. However, the relationship between sexual dysfunction and emotional response to sexual arousal in male patients with schizophrenia remains unclear. This study aimed to assess the incidence, risk factors of sexual dysfunction in males, and their clinical correlations to sexual arousal in male patients with schizophrenia in China.MethodsA total of 162 male patients, aged 18–50 years, with schizophrenia were recruited from a psychiatric hospital in Ganzhou. The clinical symptoms were assessed by the Positive and Negative Syndrome Scale (PANSS). The Arizona Sexual Experience Scale was utilized to evaluate sexual dysfunction. Erotic images were selected from International Affective Picture System (IAPS). Sixty-eight out of the 162 subjects completed the erotic pictures reactivity task.ResultsOverall, 48 (29.6%) patients were measured as having global sexual dysfunction, 72 (44.4%) patients as having strength of sex drive dysfunction, 51 (31.5%) patients as having sexual arousal dysfunction, 55 (34.0%) patients as having penile erection dysfunction, 60 (37.0%) patients as having reached orgasm dysfunction, and 60 (37.0%) patients as having satisfaction with orgasm dysfunction. The sexual dysfunction patients had significantly higher scores on the negative symptoms of the PANSS. The only important predictor of sexual dysfunction was the severity of PANSS negative factor. The sense of pleasure and arousal post viewing erotic images in the sexual dysfunction group were lower compared to the non-sexual dysfunction group. The sense of pleasure and approach motivation were significantly negatively correlated with the severity of sexual dysfunction.ConclusionsThis study shows that nearly one-third of young and middle-aged chronically medicated male inpatients with schizophrenia suffer from sexual dysfunction. The negative factor of the PANSS can be regarded as the risk factor of sexual dysfunction. Schizophrenia patients with sexual dysfunction experienced lower pleasure and higher avoidance motivation than non-sexual dysfunction patients when exposed to erotic stimuli.

Download Full-text

Sexual Dysfunction in Drug-Naive or Drug-Free Male Patients with Psychosis: Prevalence and Risk Factors

Indian Journal of Psychological Medicine ◽

10.4103/ijpsym.ijpsym_1_19 ◽

2019 ◽

Vol 41 (5) ◽

pp. 434-439 ◽

Cited By ~ 1

Author(s):

Dhananjayan Ravichandran ◽

Rajesh Gopalakrishnan ◽

Anju Kuruvilla ◽

K. S. Jacob

Keyword(s):

Risk Factors ◽

Sexual Dysfunction ◽

Drug Naïve ◽

Male Patients ◽

Drug Free

Download Full-text

Risk Factors Associated with Primary and Secondary Reduced Libido in Male Patients with Sexual Dysfunction

Journal of Sexual Medicine ◽

10.1111/jsm.12043 ◽

2013 ◽

Vol 10 (4) ◽

pp. 1074-1089 ◽

Cited By ~ 51

Author(s):

Giovanni Corona ◽

Giulia Rastrelli ◽

Valdo Ricca ◽

Emmanuele A. Jannini ◽

Linda Vignozzi ◽

...

Keyword(s):

Risk Factors ◽

Sexual Dysfunction ◽

Factors Associated ◽

Male Patients

Download Full-text

A Multivariate Analysis of Perioperative Risk Factors on the 10 Year Survival of Patients with Acute Type A Aortic Dissection

The Thoracic and Cardiovascular Surgeon ◽

10.1055/s-0036-1571542 ◽

2016 ◽

Vol 64 (S 01) ◽

Author(s):

A. Engel ◽

C. Fiessler ◽

M. Weyand ◽

F. Harig

Keyword(s):

Risk Factors ◽

Multivariate Analysis ◽

Aortic Dissection ◽

Type A ◽

Perioperative Risk ◽

Acute Type ◽

Type A Aortic Dissection ◽

Perioperative Risk Factors

Download Full-text

Therapeutic options in male osteoporosis

Osteologie/Osteology ◽

10.1055/s-0038-1630134 ◽

2013 ◽

Vol 22 (04) ◽

pp. 271-276 ◽

Cited By ~ 1

Author(s):

P. Farahmand ◽

J. D. Ringe

Keyword(s):

Risk Factors ◽

Vitamin D ◽

Public Health Problem ◽

Male Osteoporosis ◽

Individual Risk ◽

Modes Of Action ◽

Increased Risk ◽

Study Results ◽

Long Term Treatment ◽

Male Patients

SummaryOsteoporosis in men is increasingly recognized as an important public health problem but affected patients are still under-diagnosed and -treated. As in women the diagnostic and therapeutic strategy has to be adapted to the individual case. In the practical management it is very important to detect possible causes of secondary osteoporosis, to explain the possibilities of basic therapy counteracting individual risk factors and communicate that osteoporosis is a chronic disease and adherence to a long-term treatment is crucial. In established severe osteoporosis a careful analgesic therapy is important to avoid further bone loss related to immobility. In elderly men with increased risk of falling insufficient Vitamin D supply or impaired activation of Vitamin D due to renal insufficiency must be taken into consideration. Specific medications available today for the treatment of male osteoporosis comprise among antiresorptive drugs the bis phosphonates alendronate, risedronate and zoledronic acid. Denosumab, the first biological therapy is approved for men with androgen deprivation therapy for prostate cancer. An important advantage of this potent antiresorptive drug is the increased adherence due to the comfortable application by sixmonthly subcutaneous injections. Study results from the 2-year multi-center randomized controlled ADAMO-Study will very soon allow the use of denosumab in all types of male osteoporosis. Teriparatide, the 34 N-terminal amino acid sequence of parathyroid hormone was approved for men with osteoporosis as an anabolic agent based on proven efficacy by different studies. Among drugs with other modes of action the D-hormone pro-drug alfacalcidol can be used in men alone or in combination with the advantage of pleiotropic effects on calcium absorption, parathyroids, bone and muscle. Recently also Strontium-ranelate was approved for male patients with the limitation to exclude men with clinical relevant cardiovascular risk factors. In general the possibilities to treat male osteoporosis have considerably improved during recent years. Today there is a choice of a spectrum of drugs from mild to strong potency with different modes of action on bone turnover to design strategies for individual male patients.

Download Full-text